Dan Rujescu (Germania)
Klinik und Poliklinik für Psychiatrie und Psychotherapie
Nußbaumstr. 7, 80336 München
Tel. (089) 5160-5756, Fax. (089) 5160-5779
Dan Rujescu is Full Professor of Psychiatry, Genomics and Neurobiology. He received his medical degree from the Universities Heidelberg and Essen, Germany. In 1997 he became head of the Division of Molecular and Clinical Neurobiology at the University of Munich. He is deputy head of the Department of Psychiatry, head of the Alzheimer Memorial Centre and the Geriatric Psychiatry Branch as well as director of the Genetics Research Centre at the University of Munich. Dan Rujescu is involved extensively in national and international genome and post-genome efforts to understand the genetics and pathophysiology of neuropsychiatric disorders. His group has recruited and characterized a large sample of patients and controls (n=4,500) adding a complementary approach on intermediate phenotypes. He is involved in several large scale international studies using and developing the newest technologies, including genome-wide association and copy-number variation studies (e.g. SGENE, WTCCC2, MOODS, GERAD, PGC, CGASP, COGENT, CIAC). He has co-authored over 120 original publications (cumulative IF 900), including two in Nature (one first author), five in Nature Genetics and one in Nature Medicine. He received various awards including the NARSAD Independent Investigator Award (William & Gloria Paul Family Foundation), the Kraepelin Research Award, the Dr. Paul Janssen Schizophrenia Research Award, the Kraepelin-Alzheimer-Award, and the European BMS Prevention Award in Psychiatry. He is involved in editorial boards of several journals [e.g. Section Editor for BMC Medical Genetics, Field Editor for Molecular Psychiatry for the World Journal of Biological Psychiatry (by the World Federation of the Societies of Biological Psychiatry, WFSBP), and member of various Editorial Boards including International Journal of Neuropsychopharmacology (by the Collegium Internationale Neuro-Psychopharmacologicum, CINP), European Neuropsychopharmacology (by the European College of Neuropsychopharmacology, ECNP), and Journal of Medical Genetics]. Furthermore, he is chair and member of several Task Forces of international scientific societieties; member of Steering Committee „Molecular genetics“ of the German Research Network on Depression and Suicidality, of the Steering Committee „Molecular genetics“ of the German Research Network on Schizophrenia; Councillor of the CINP, and Head of the Section Genetics and Endophenotypes of the German Society of Biological Psychiatry. Furthermore, he had been involved in the organization of numerous large international scientific congresses and was co-chair of several scientific and organization committees, e.g. the 7th World Congress of Biological Psychiatry (WCBP, 6000 attendees), the 13th EPS Congress (2600 attendees), the 26th CINP (3500 attendees), the 9th WCBP (4000 attendees). Since 2009 he is Co-Chair of the International Scientific Program Committee of the 10th WCBP.
George Calin (USA)
University of Texas M. D. Anderson Research Trust, Associate Professor, Dept. Experimental Therapeutics1515 Holcombe Blvd. Houston, Texas 77030-4009, tel 713-792-5461, mailto:firstname.lastname@example.org
Geoege Calin received both M.D. and Ph.D. degrees at Carol Davila University of Medicine in Bucharest, Romania. After working cytogenetics as undergraduate student with Dr. Dragos Stefanescu in Bucharest, he completed a cancer genomics training in Dr. Massimo Negrini’s laboratory at University of Ferrara, Italy. In 2000 he became a postdoctoral fellow at Kimmel Cancer Center in Philadelphia, PA, and while working in Dr. Carlo Croce laboratory they were the first to discover the link between human cancers and microRNAs, a finding considered as a milestone in microRNA research history. He is presently a Fellow of The University of Texas M. D. Anderson Research Trust and appointed as a tenure-track Associate Professor in Experimental Therapeutics Department. He developed starting from July 2007 an independent research group and produced a new advance by linking a new class of non-coding RNAs to cancers, namely the ultraconserved genes. The main focus of his laboratory is to study the roles of microRNAs and other non-coding RNAs in cancer initiation and progression, as well as the mechanisms of cancer predisposition linked to ncRNAs. He explores also new RNA therapeutic options for cancer patients. Furthermore, a long-term goal is to establish at MDACC an institute for the study of non-codingRNAs in cancer with particular focus on the use of non-codingRNAs as drugs or as targets for drug therapy.
Lucian R. Chirieac (USA)
Harvard Medical School, Department of Pathology, Brigham and Women's Hospital,
75 Francis Street, Boston, MA 02465
Phone: 617-732-8126, Fax: 617-264-5118, mailto:email@example.com
Dr. Chirieac is Associate Professor of Pathology at Harvard Medical School and Staff Pathologist at the Brigham and Women's Hospital in Boston, Massachusetts. He is the recipient of three NIH grants, and currently the co-director of the Specialized Programs of Research Excellence (SPORE) in Lung Cancer Grant at the Dana-Farber/Harvard Cancer Center. In the past five years he has authored and co-authored more than sixty papers published in peer-reviewed journals. He is a member in eight prestigious professional societies and one of the twelve permanent members of the International Association for the Study of Lung Cancer that establishes diagnostic standards and therapeutic guidelines for the treatment of lung cancer. He is the only pathologist that is a member of the National Comprehensive Cancer Network NCCN who co-authored the Non-Small Cell Lung Cancer Guidelines that establishes international guidelines for the treatment of lung cancer. He has reviewed important articles for consideration for publication in the most prestigious peer-reviewed journals and he is the principal pulmonary oncologic pathologist and investigator at the Brigham and Women’s Hospital. He has been involved in the training and supervision of many physicians, particularly in the specialty of Pathology. He has received many honors and awards and participated in high profile national and international scientific meetings.